Editas Medicine Inc Revenue per Employee (EDIT), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Editas Medicine Inc   (NASDAQ: EDIT)
 

Editas Medicine Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 232.31% in the second quarter 2026, year on year to cumulative value of $47 million, Editas Medicine Inc 's revenue per employee grew on a trailing twelve months basis to $ 540,287. The productivity of Editas Medicine Inc 's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 208 other companies have achieved higher revenue per employee. While Editas Medicine Inc 's total ranking has deteriorated compared to the previous quarter from 726 to 1802. Editas Medicine Inc has 87 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EDIT Revenue per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Revenue Change 232.31 % -39.22 % -19.16 % 12265.57 % 597.47 %
Sales per Employee (TTM) $ 540,287 444,747 465,747 533,149 447,149
EDIT's Total Ranking # 1802 # 726 # 1897 # 0 # 2060
Seq. Revenue Change 319.99 % -88.56 % 228 % 110.82 % -23.19 %

EDIT Company Profile >> Back to EDIT Efficiency Comparisons >> Compare EDIT Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 209
Overall Market # 1802

Revenue per Employee Statistics
High Average Low
$ 1,052,839 $ 418,342 $ 64,816
(Sep 30 2020)   (Jun 30 2017)



Financial Statements
Editas Medicine Inc 's Revenue MRQ $ 12 Millions Visit EDIT's Income Statement
Editas Medicine Inc 's Revenues TTM $ 47 Millions Visit EDIT's aggregate revenue growth
What are EDIT's Sales? Visit EDIT's Sales by Segment




Other Ratios
Editas Medicine Inc 's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
EDIT's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for EDIT's Competitors
Revenue per Employee for EDIT's Suppliers
Revenue per Employee for EDIT's Customers

You may also want to know
EDIT's Sales Growth Rates EDIT's Pe Price to earnings ratio EDIT's Receivables Turnover Ratio EDIT's Stock Quote
EDIT's Net Income Growth Rates EDIT's Ps Price to Sales ratio EDIT's Sales per Employee EDIT's Asset Turnover Ratio
EDIT's Net Margin EDIT's Pb Price to Book ratio EDIT's Financial Strength Ratios EDIT's Dividend Payout Ratio
Date modified: 2026-09-08T17:29:50+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Arrowhead Pharmaceuticals Inc   941,624.47 $ 669.495  Million 711 
Scilex Holding Company  929,647.06 $ 31.608  Million 34 
Ardelyx inc   922,073.62 $ 450.894  Million 489 
The Oncology Institute Inc   916,137.29 $ 587.244  Million 641 
Pacira Biosciences inc   900,077.20 $ 746.164  Million 829 
Fortress Biotech Inc   897,217.95 $ 69.983  Million 78 
Alphatec Holdings Inc   892,420.59 $ 814.780  Million 913 
Merck and Co Inc   887,586.67 $ 66,569.000  Million 75,000 
Nektar Therapeutics  866,492.06 $ 54.589  Million 63 
Carlisle Companies Incorporated  863,898.31 $ 5,097.000  Million 5,900 
Verastem Inc   858,098.04 $ 87.526  Million 102 
Emergent Biosolutions Inc   855,777.78 $ 770.200  Million 900 
Bridgebio Pharma Inc   849,903.46 $ 713.069  Million 839 
Pfizer Inc  849,280.00 $ 63,696.000  Million 75,000 
Syndax Pharmaceuticals Inc   845,651.01 $ 252.004  Million 298 
Xilio Therapeutics Inc   843,315.79 $ 64.092  Million 76 
Axsome Therapeutics Inc   839,534.05 $ 776.569  Million 925 
Ionis Pharmaceuticals Inc   834,107.70 $ 1,169.419  Million 1,402 
Vir Biotechnology Inc   826,231.61 $ 303.227  Million 367 
Immunocore Holdings Plc  822,089.69 $ 430.775  Million 524 
Prothena Corporation Public Limited Company  813,880.60 $ 54.530  Million 67 
Alkermes Plc   813,488.78 $ 1,667.652  Million 2,050 
Lifevantage Corp  811,421.52 $ 180.947  Million 223 
Sanuwave Health Inc   798,236.36 $ 43.903  Million 55 
Geron Corporation  791,864.34 $ 204.301  Million 258 
Adma Biologics Inc   789,697.06 $ 510.934  Million 647 
Vericel Corporation  769,605.53 $ 306.303  Million 398 
Cerus Corporation  768,138.89 $ 221.224  Million 288 
Septerna Inc   760,630.77 $ 98.882  Million 130 
Dyadic International Inc   760,447.40 $ 3.802  Million 5 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.